Abeona (ABEO) Reports $11.4M Q2 Revenue Growth of 31%

On August 13, Abeona Therapeutics (NASDAQ: ABEO) reported second-quarter revenue of $11.4 million, up 31% from $8.7 million in the prior quarter. The company has treated 12 patients with its gene therapy ZEVASKYN, expanding its treatment center network to seven sites, including Cincinnati Children's. Despite the revenue growth, net losses widened to $20.2 million, or $0.35 per share. The company's new technology payment from Medicare, effective October 1, 2026, highlights ongoing support for its innovative treatments, making it relevant for investors monitoring biotech advancements.